Initiate Phase 3 fixed-dose combination trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 22 Jan 2024
- Due
- 31 Mar 2024
- Delivered
- 12 Mar 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“1Q 2024: Initiate Phase 3 fixed-dose combination (“FDC”) trial”
What we found
Evidence strength D What the grades mean
NewAmsterdam initiated Phase 3 TANDEM fixed-dose combination trial on March 12, 2024, meeting the Q1 2024 deadline.
-
D NewAmsterdam Pharma Announces 2024 Strategic Priorities Initial announcement of plan to initiate TANDEM in 1Q 2024
-
D NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Press release announcing dosing of first patient and initiation of TANDEM trial in March 2024
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you NewAmsterdam Pharma Co N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-NAMSW-000038 · Corrections policy